抗SSA/Ro抗体对系统性红斑狼疮患者妊娠结局的影响
基于LUNA注册库2016-2022年数据,回顾性分析247例SLE患者首次妊娠,发现抗磷脂抗体(aPL)与胎儿丢失相关(OR 2.46),而抗SSA/Ro抗体与胎儿丢失无关(OR 1.32),但抗SSA/Ro可能影响胎儿发育,需进一步研究。
要点
- aPL与SLE患者胎儿丢失相关(OR 2.46,95%CI 1.21-5.01)。
- 抗SSA/Ro抗体与胎儿丢失无关(OR 1.32,95%CI 0.64-2.74)。
- 抗SSA/Ro阳性与阴性组活产率和早产率无差异。
核心结论
- aPL与SLE患者胎儿丢失相关,而抗SSA/Ro抗体与胎儿丢失无关。
- 抗SSA/Ro可能影响胎儿发育,需进一步研究。
研究设计与样本
- 回顾性提取LUNA注册库(2016-2022年,n=1775)中SLE发病后首次妊娠数据,排除抗SSA/Ro状态或妊娠结局不明及流产病例。
- 采用两组比较和logistic回归(调整aPL)分析APOs相关因素及抗SSA/Ro抗体的影响。
主要发现
- 247次妊娠包括194次活产(122足月、57早产、15不清)和53次胎儿丢失。
- 多因素logistic回归显示胎儿丢失与aPL(OR 2.46,95%CI 1.21-5.01)和甲泼尼龙冲击史(OR 2.89,95%CI 1.39-6.00)相关,与抗SSA/Ro无关(OR 1.32,95%CI 0.64-2.74)。
- 抗SSA/Ro阳性(n=145)与阴性(n=102)组活产率(77% vs 80%,P=0.64)和早产率(31% vs 33%,P=0.87)无差异。
- 小样本亚组临床结局(抗SSA/Ro阳性 vs 阴性):出生体重2402±586 g vs 2608±449 g(P=0.20);小于胎龄儿50% vs 8%(P=0.11);低出生体重儿67% vs 38%(P=0.25)。
关键数值与推荐
- 胎儿丢失与aPL相关OR 2.46(95%CI 1.21-5.01),与甲泼尼龙冲击史相关OR 2.89(95%CI 1.39-6.00)。
- 抗SSA/Ro与胎儿丢失无关OR 1.32(95%CI 0.64-2.74)。
- 抗SSA/Ro阳性 vs 阴性活产率77% vs 80%(P=0.64),早产率31% vs 33%(P=0.87)。
临床怎么用
- SLE妊娠患者应关注aPL状态和甲泼尼龙冲击史以评估胎儿丢失风险。
- 抗SSA/Ro抗体阳性不增加胎儿丢失风险,但可能影响胎儿发育,需加强监测。
局限性
- 回顾性研究设计。
- 排除了抗SSA/Ro状态或妊娠结局不明及流产病例。
- 亚组分析样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to investigate the influence of anti-SSA/Ro antibodies and other factors on adverse pregnancy outcomes (APOs) in patients with SLE. METHODS: We retrospectively extracted data on first pregnancies after SLE onset from the Lupus Registry of Nationwide Institutions (LUNA, 2016-2022, n = 1775). We excluded patients with unclear anti-SSA/Ro status or pregnancy outcomes and cases of abortion. We used two-group comparison and logistic regression, adjusting for aPL, to analyse factors related to APOs and the influence of anti-SSA/Ro antibodies. RESULTS: The 247 pregnancies included 194 live births (122 full-term, 57 preterm, 15 unclear) and 53 foetal losses. Multivariate logistic regression showed foetal loss was associated with aPL [odds ratio (95% CI): 2.46 (1.21-5.01)] and a history of methylprednisolone pulse [2.89 (1.39-6.00)], but not anti-SSA/Ro [1.32 (0.64-2.74)]. No differences were found between anti-SSA/Ro positive (n = 145) and negative (n = 102) groups regarding live birth (anti-SSA/Ro positive vs negative, 77% vs 80%, P = 0.64) or preterm birth (31% vs 33%, P = 0.87). Clinical outcomes in a small subgroup were as follows (anti-SSA/Ro positive vs negative): birthweight, 2402 ± 586 g vs 2608 ± 449 g (P = 0.20); small for gestational age infants, 50% vs 8% (P = 0.11); and low birthweight infants, 67% vs 38% (P = 0.25). CONCLUSION: aPL showed an association with foetal loss in SLE, while anti-SSA/Ro antibodies did not. Anti-SSA/Ro may influence foetal development, necessitating further research.
引用
- Yamaguchi E, Tsuji H, Ogawa A, et al. The impact of anti-SSA/Ro antibodies on pregnancy outcomes in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2026. PMID: 41838414. doi:10.1093/rheumatology/keag122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。